Global Syndromic Diagnostic Test Market Growth (Status and Outlook) 2024-2030

Global Syndromic Diagnostic Test Market Growth (Status and Outlook) 2024-2030

Syndromic diagnostic test is a type of medical test that enables the simultaneous detection and identification of multiple pathogens or disease markers associated with a specific syndrome or set of symptoms. Instead of targeting a single pathogen or condition, syndromic tests utilize advanced technologies like multiplex PCR, microarrays, or next-generation sequencing to identify a range of pathogens or genetic markers in a single analysis. These tests are particularly useful in situations where the exact cause of an illness is unknown or when there is a possibility of multiple disease agents contributing to the symptoms.

The global Syndromic Diagnostic Test market size is projected to grow from US$ million in 2023 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.

LPI (LP Information)' newest research report, the “Syndromic Diagnostic Test Industry Forecast” looks at past sales and reviews total world Syndromic Diagnostic Test sales in 2023, providing a comprehensive analysis by region and market sector of projected Syndromic Diagnostic Test sales for 2024 through 2030. With Syndromic Diagnostic Test sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Syndromic Diagnostic Test industry.

This Insight Report provides a comprehensive analysis of the global Syndromic Diagnostic Test landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Syndromic Diagnostic Test portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Syndromic Diagnostic Test market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Syndromic Diagnostic Test and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Syndromic Diagnostic Test.

United States market for Syndromic Diagnostic Test is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Syndromic Diagnostic Test is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Syndromic Diagnostic Test is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Syndromic Diagnostic Test players cover Abbott, Hologic, Applied BioCode, Danaher and Diagenode, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Syndromic Diagnostic Test market by product type, application, key players and key regions and countries.

Segmentation by type
Nucleic Acid Extraction Test
Polymerase Chain Reaction (PCR) Test
Others

Segmentation by application
Hospital
Laboratory
Research Institution
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Abbott
Hologic
Applied BioCode
Danaher
Diagenode
Curetis
Bio-Rad
DiaSorin
bioMérieux
QIAGEN

Please note: The report will take approximately 2 business days to prepare and deliver.